PR IMV to Host a Webcast to Highlight its Immune-Educating DPX® Platform
Event will feature Michael Kalos, Ph.D., member of IMV’s Board of Directors and internationally recognized expert in T cell therapy and immunotherapy
Live webinar on Thursday, February 24th @ 8amET, registration details below
DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platform to treat solid and hematological cancers, today announced that it is hosting a Research and Development Day” via webcast on Thursday, February 24, 2022 at 8:00am Eastern Time to highlight the differentiating features of its patented DPX delivery platform.
IMV’s DPX technology is a delivery platform that can incorporate a range of bioactive molecules to produce targeted, long-lasting immune responses enabled by various formulated components. This versatile, immune-educating technology is being developed for application in a variety of therapeutic areas (e.g., oncology, infectious disease) where generation of a target-specific immune response is expected to mitigate disease.
The webcast will feature a presentation by Michael Kalos, Ph.D., Key Opinion Leader (KOL) and member of IMV’s board of directors, who will discuss the potential of IMV’s DPX delivery platform in addressing unmet medical needs in the current and future oncology landscape.
The IMV team will describe the DPX delivery platform technology and its differentiated immune-educating capabilities, highlighting key advantages demonstrated in both clinical and preclinical studies including its favorable safety profile. IMV management will also provide an update on the Company’s clinical programs and discuss key expected milestones in 2022. A live question and answer session will follow.
To register for the Research and Development Day, please click here.